Brintellix® (vortioxetine) statistically significantly improves cognitive functioning (†) and functional capacity in patients with major depressive disorder (MDD) (1)

†Brintellix® demonstrated improved cognitive symptoms (DSST) and functional capacity (UPSA) in MDD (statistically significant vs. placebo, p<0.05).

In this randomised, placebo-controlled, active-reference, double-blind, flexible-dose study on the efficacy of Brintellix® on cognitive function in MDD, Brintellix® statistically significantly improved everyday functioning in patients with MDD (p<0.001) as measured by the UPSA, which is a measure of ability to perform daily tasks.1

Explore the data in more detail below.

Change in UPSA composite score from baseline at week 81

***p<0.001 vs. placebo; NS, not significant.
Duloxetine was included as active reference for study validation, not for comparison of effect sizes.
UPSA data presented are a composite of UPSA-VIM and UPSA-B.

Adverse events that occurred in Brintellix® treated patients in the course of the MDD short-term, placebo-controlled studies with an incidence ≥10% were headache and nausea. Other adverse events include: vomiting; diarrhoea; constipation; dizziness; generalised pruritus; hyponatraemia.2
For full information please see the Product Information.

 

Abbreviations

DSST, digit symbol substitution test; MDD, major depressive disorder; NS, not significant; UPSA, University of San Diego performance-based skills assessment; UPSA-B, UPSA–brief form; UPSA-VIM, UPSA–Validation of intermediate measures.

References

  1. Mahableshwarkar AR et al. Neuropsychopharmacol 2015; 40(8): 2025-2037
  2. Brintellix® Australian Approved Product Information.

Internal ID: AU-BRIN-0480. September 2022.

  • Brintellix
    Body

    Brintellix® é indicado para o tratamento de episódios depressivos major em adultos

  • footer text
    Body

    A informação contida nesta página destina-se exclusivamente a profissionais de saúde.

    Recebeu este e-mail porque consentiu anteriormente em receber e-mails da Lundbeck.
    Brintellix® é uma marca registrada da H/Lundbeck A/S.

    Representante local do Titular da Autorização de Introdução no Mercado:

    Lundbeck Portugal

    Quinta da Fonte
    Rua Quinta da Fonte, Nº 13
    Edifício Q34 Forum, Piso 1, Fração F
    2770-192 Paço de Arcos. Portugal
    NIF 503573922

    Tlf.: +351 21 004 5900 | Fax: +351 21 004 5999

    www.lundbeck.pt